Evolution of the Average Target: GSK plc

Data source: GSK plc(GSK)
Evolution of the Average Target - GSK plc

Evolution of the Target Price: GSK plc

Data source: GSK plc(GSK)
Evolution of the Target Price - GSK plc

Changes in Analyst Recommendations: GSK plc

Data source: GSK plc(GSK)
a26be79be5c9108.TpLkjwviquhB2gOV_KjPt2Mxt1prZgdfbrLBvWvkh3Q.Y9q1_VSB-t8xmFXwr8Gg3TID2yJTJHUaAuO28FOe9g1jyLb2QdCarC6_Tg~353c6b28967ec62a33300c31005d5c2f
10-27 GSK plc : RBC remains Neutral ZD
10-26 GSK plc : JP Morgan reaffirms its Sell rating ZD
10-21 GSK plc : JP Morgan keeps a Sell rating ZD
10-19 GSK plc : Jefferies reiterates its Buy rating ZD
10-15 GSK plc : UBS remains Neutral ZD
10-14 Berenberg still a buyer of GSK, considering stock undervalued Zonebourse
10-14 GSK plc : Berenberg remains its Buy rating ZD
10-14 GSK's Pharma Business to Drive Future Returns Amid Oncology Boost, Berenberg Says MT
10-14 RBC Expects 'In-line' Q3 Results for GSK as Strong HIV, Asthma Drug Sales Offset Vaccine Softness MT
10-13 GSK Likely to Deliver In-Line Q3, RBC Says MT
10-13 GSK plc : RBC gives a Neutral rating ZD
10-08 GSK plc : Gets a Sell rating from JP Morgan ZD
10-07 GSK plc : Berenberg remains its Buy rating ZD
10-01 GSK plc : JP Morgan reiterates its Sell rating ZD
09-29 GSK plc : Gets a Neutral rating from Deutsche Bank ZD
09-29 GSK plc : Jefferies keeps its Buy rating ZD
09-18 GSK plc : Deutsche Bank remains Neutral ZD
09-17 GSK plc : UBS is Neutral ZD
09-16 AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down MT
09-15 GSK plc: Priced for the storm, being built for thereafter Alphavalue
09-15 GSK Upgraded to Buy as Berenberg Notes Pipeline Momentum; Price Target Raised MT
09-15 Berenberg Upgrades GSK to Buy, Raises PT MT
09-15 Berenberg Upgrades GSK to Buy From Hold, Raises Price Target to $60 From $54 MT
09-15 Berenberg likes GSK; Deutsche Bank lifts Astra AN
09-15 GSK plc : Deutsche Bank remains Neutral ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+4.27%
+4.92%
-0.68%
-2.56%
+13.62%
-2.85%
+22.47%
-10.64%
+0.95%
Average +3.28%
Weighted average by Cap. +3.54%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
19.24GBP
Average target price
21.75GBP
Spread / Average Target
+13.07%
High Price Target
30.10GBP
Spread / Highest target
+56.49%
Low Price Target
14.55GBP
Spread / Lowest Target
-24.36%

Analyst Consensus Detail

Analyst consensus - GSK plc

Consensus revision (last 18 months)

Consensus revision (last 18 months) - GSK plc
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - GSK plc